Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities.
Malacarne
P
P
Maestri
A
A
D000230:Adenocarcinoma / Q000188:drug therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000188:drug therapy; D011517:Prothrombin Time; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D014859:Warfarin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate